ESMO 2024: Treatment of uHCC - Episode 15
Importance of Real-World Data in Supporting Treatment Options
Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.
Video content above is prompted by the following:
Dr. El- Khoueiry: Real-world data gives a different perspective on approved treatments,: essentially, how the therapy performs off -trial. Please discuss the findings from the real-world study focusing on real-world eligibility for cabozantinib, regorafenib, and ramucirumab in second-line treatment.
• Discuss the difference in strict eligibility criteria (SEC) compared towith liberal modified eligibility criteria [MEC, including ECOG score of 2, and Child-Pugh- score of B7] (Fung AS, et al. Cancer Med. 2020).
Related Content:
